Biopharma Funding Rounds Advance Clinical Development
Biopharmaceutical funding surges as companies like Veradermics, Peptilogics, and BridGene advance innovative therapies through significant financing rounds.
The momentum of funding in biopharmaceutical continues, as organizations focus on advancing R&D for respective leading therapy and treatment candidates undergoing clinical testing.
- Veradermics Inc.
- Peptilogics
- BridGene Biosciences
Veradermics announced the completion of an oversubscribed $150 million Series C financing round.
The funding is expected to support the registrational development and planned New Drug Application submission for Veradermics’ lead investigational product, VDPHL01.
VDPHL01 holds potential to be the first and only extended-release oral minoxidil treatment designed specifically for hair regrowth in women and men.
Author's summary: Biopharma companies secure funding for innovative therapies.